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Abstract
Objective: Sudden acquired retinal degeneration syndrome (SARDS) is one of the 
leading causes of acute blindness in dogs, with an unknown etiology and no effective 
treatment. Certain breeds such as Dachshunds are overrepresented among SARDS 
patients, and therefore, the syndrome is suspected to have a genetic component. The 
objective of this study was to determine if a genetic locus associated with SARDS in 
Dachshunds could be identified using a genome‐wide association study (GWAS).
Procedures: Genome‐wide association mapping was performed in 15 SARDS‐af-
fected and 16 unaffected Dachshunds. Genotyping of three classical DLA class II 
genes (DLA‐DRB1, DLA‐DQA1, and DLA‐DQB1) was performed in 34 SARDS‐af-
fected and 66 unaffected Dachshunds to evaluate for an association in this region.
Results: Although no single nucleotide polymorphisms (SNPs) were of genome‐
wide statistical significance (PBonferroni < 0.05), 5 of the top 9 SNPs were in the major 
histocompatibility complex (MHC). Using DLA typing, the allele DLA‐DRB1*09401 
was identified as a risk factor for the development of SARDS (P = 0.0032, OR = 4.0). 
The alleles DLA‐DQB1*00101 (P = 0.0050, OR = 0.31), DLA‐DQA1*00901 
(P = 0.0087, OR = 0.33), and a previously identified DLA‐DRB1 allele described as 
“DRB1‐T” (P = 0.0284, OR = 0.37) were identified as protective factors.
Conclusions: Although far from definitive, association of SARDS with alleles of 
immunologic importance further supports the hypothesis that autoimmunity may 
play a role in the pathogenesis of SARDS.
K E Y W O R D S
Dachshund, DLA, dog leukocyte antigen, genome‐wide association studies, MHC, sudden acquired 
retinal degeneration syndrome
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1 |  INTRODUCTION
Sudden acquired retinal degeneration syndrome (SARDS) 
is a common cause of irreversible blindness in dogs.1 The 
disease is typically acute in onset and characterized by an 
initially normal fundic appearance despite an extinguished 
electroretinogram. Currently, the etiology of SARDS re-
mains unknown and there is no proven treatment for the 
condition, although several different etiologic hypothe-
ses exist and several therapeutic approaches have been 
suggested. Because dogs with SARDS often present with 
concurrent systemic signs such as polyuria, polydipsia, 
polyphagia, lethargy, and weight gain, as well as labora-
tory abnormalities consistent with hyperadrenocorticism, 
some researchers hypothesize that SARDS is an endocrine 
disorder.1 In one study, >90% of dogs with SARDS had 
elevated adrenal sex hormone and/or cortisol serum con-
centrations.2 By contrast, others suggest that SARDS is the 
canine equivalent of autoimmune retinopathy (AIR)—a 
disease of humans in which antiretinal antibodies result in 
vision loss and severe attenuation or loss of retinal electri-
cal activity, with minimal changes in funduscopic appear-
ance.3,4 In one study, an autoantibody to neuron‐specific 
enolase (NSE)—a glycolytic enzyme found in photorecep-
tors, neurons, and neuroendocrine tissues—was identified 
in 6 of 24 dogs with SARDS, while no control dogs had 
detectable autoantibodies.5
In 2014, the American College of Veterinary 
Ophthalmologists’ Vision for Animals Foundation hosted a 
think tank to prioritize goals for future SARDS research.1 
One of their specific recommendations was to use genome‐
wide association studies (GWAS) to identify genetic factors 
that may contribute to an understanding of the etiologic and 
pathogenic mechanisms of the disease. This technology uses 
single nucleotide polymorphisms (SNPs) at thousands of loci 
across the entire canine genome to identify regions of genetic 
difference between control and affected animals. If a statisti-
cally significant association is found between a region of the 
canine genome and the disease of interest, candidate genes 
within the region can be identified for further investigation. 
Identification of a genetic association would increase under-
standing of SARDS, refine the direction of future research, 
and could ultimately lead to the development of treatments 
and identification of at‐risk patients. Furthermore, it could 
support or refute the hypothesis that SARDS may serve as a 
spontaneous canine model for AIR.
A recent retrospective study conducted at the University 
of California‐Davis Veterinary Medical Teaching Hospital 
(UCD‐VMTH) identified several breeds that were overrep-
resented in the SARDS patient population.6 Dachshunds, in 
particular, were 8‐fold overrepresented, which is consistent 
with previous reports7 and may indicate a genetic component 
of the disease. Therefore, the purpose of the present study 
was to use genome‐wide association to investigate genetic as-
sociations with SARDS in Dachshunds.
2 |  MATERIALS AND METHODS
2.1 | Animals
This study was approved by the Institutional Animal Care 
and Use Committee at the University of California‐Davis 
(Protocol #18719) and performed in accordance with the 
Association for Research in Vision and Ophthalmology's 
guidelines for the use of animals in research. Blood sam-
ples were collected from SARDS‐affected and unaffected 
Dachshunds at the UCD‐VMTH, as well as from animals re-
cruited through outreach to veterinary ophthalmologists and 
to Dachshund breed organizations within the United States.
Inclusion criteria for SARDS‐affected Dachshunds included 
sudden and complete vision loss, examination and diagnosis by 
a board certified veterinary ophthalmologist or ophthalmology 
resident in training, a bilaterally extinguished electroretinogram 
(ERG), and lack of an explanation for sudden and complete vi-
sion loss on fundic examination (eg, total retinal separation, dif-
fuse severe chorioretinitis). Dogs diagnosed with SARDS were 
excluded from the current study if they had intraocular abnor-
malities impeding adequate visualization of the ocular fundus. 
All Dachshunds in the control population were >8 years old, 
had an intact menace response and/or pupillary light reflexes, 
and were reported to be visual by their owner. Dachshunds 
<8 years of age were excluded in order to avoid dogs that may 
be genetically predisposed to SARDS but had not yet devel-
oped signs of the syndrome. Exclusion criteria for control dogs 
included Cushing's disease, progressive retinal atrophy, notable 
regions of retinal degeneration or detachment on fundic exam-
ination, and/or an abnormal ERG in one or both eyes.
With the exception of one sample that did not have 
enough DNA remaining after the GWAS, all DNA samples 
used for the GWAS were also used in major histocompat-
ibility complex (MHC) genotyping. Additional control and 
SARDS‐affected dogs were recruited for MHC genotyping, 
and a number of control DNA samples were obtained from 
the Canine Genetics Biorepository (CGB), a database of 
gDNA samples collected from VMTH patients (Protocol # 
20356). The CGB DNA samples were only used if medical 
record review demonstrated that they met the same inclusion 
criteria listed above.
2.2 | Genome‐wide association study
Whole blood from affected and control dogs was collected 
into tubes containing ethylenediaminetetraacetic acid, DNA 
was extracted using the Puregene kit (Qiagen, CA), and DNA 
concentration was determined with a nanodrop spectropho-
tometer. DNA samples were genotyped with the Axiom™ 
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Canine Genotyping Array Set B (Applied Biosystems™, 
CA). The manufacturer's quality control metrics were ap-
plied, and SNPs with less than 90% genotyping call rates and 
a minor allele frequency over 0.05 were removed. Samples 
from affected and control Dachshunds were analyzed for 
population stratification by quantile‐quantile (Q‐Q) plots. 
Bonferroni correction was utilized to account for the number 
of tests performed. Association analysis was performed using 
PLINK software (Shaun Purcell, URL: http://pngu.mgh.har-
vard.edu/purcell/plink/).8
2.3 | MHC genotyping for DLA‐DRB1, 
DQA1, and DQB1
Direct sequencing of genomic DNA (gDNA) from af-
fected and control Dachshunds was performed using 
locus‐specific intronic primers targeting the follow-
ing 3 dog leukocyte antigen (DLA) class II genes: DLA‐
DRB1, DLA‐DQA1, and DLA‐DQB1. Forward and 
reverse primers used for these loci (respectively) were 
DRB.F (GATCCCCCCGTCCCCACAG) and DRB.R 
(TGTGTCACACACCTCAGCACCA), DQA.F (TAAGGTT 
CTTTTCTCCCTCT) and DQA.R (GGACAGATTCAGTG 
AAGAGA), and DQB.F2 (GGTTGACGGGCATCAGAG) 
and DQB.R (GGTGCGCTCACCTCGCCGCT). Each poly-
merase chain reaction (PCR) was performed with gDNA 
in a 20‐µL reaction containing 1 × PCR buffer (Applied 
Biosystems, Foster City, CA), 0.8 µmol/L of each primer, 
0.125 mmol/L dNTP, and 0.5 U of AmpliTaq Gold (ABI 
PRISM BigDye Terminator Cycle Sequencing Ready 
Reaction Kits, Original and Version 2.0 Protocol, Applied 
Biosystems). A negative control was included with each 
reaction to identify any reagent contamination. For amplifi-
cation, samples were first held at 94°C for 12 minutes then 
underwent 35 cycles of 94°C for 30 seconds; 66°C (DRB), 
57°C (DQA), or 60°C (DQB) for 30 seconds; and 72°C for 
45 seconds, followed by a final extension phase of 72°C for 
20 minutes. The final product sizes were 290 bp for DLA‐
DRB1, 312 bp for DLA‐DQA1, and 372 bp for DLA‐DQB1. 
To remove unconsumed dNTPs and primers, PCR products 
were cleaned using the ExoSap‐IT® kit (Applied Biosystems, 
CA) according to the manufacturer's protocol. Sequencing 
reactions were performed with Big Dye® terminator mix 
(Applied Biosystems, CA) using the aforementioned primers 
according to the manufacturer's protocol. The purified PCR 
products were sequenced on an ABI 3500 Genetic Analyzer 
(Applied Biosystems, CA).
2.4 | DNA allele and haplotype assignment
DRB1/DQA1/DQB1 allele determination was performed by 
comparison with annotated sequences in GenBank, begin-
ning with homozygous individuals. For heterozygotes, a com-
parison was made of GenBank sequences that most closely 
matched the sequence data, identifying the two alleles that, 
when combined, could explain all heterozygous sequencing 
calls. Three‐loci DRB1/DQA1/DQB1 haplotypes were identi-
fied in a similar manner, beginning with homozygous individ-
uals and identifying heterozygote haplotypes by comparing 
to haplotypes identified in homozygous animals.9 P‐values 
and odds ratios (OR) with 95% confidence intervals (CI) were 
calculated for allele and haplotype frequencies in SARDS‐
affected and control Dachshunds using a 2 × 2 contingency 
table. Adjustments for multiple comparisons were not per-
formed, as previously recommended for similar studies.10,11
3 |  RESULTS
3.1 | Genome‐wide association study
Using the inclusion criteria and methods outlined, DNA 
samples were prospectively collected from 16 Dachshunds 
F I G U R E  1  Genome‐wide association study (GWAS) of sudden acquired retinal degeneration syndrome (SARDS) in Dachshunds. Manhattan 
plot showing –log10 of the raw P‐values for each of 404 619 single nucleotide polymorphisms (SNPs) compared between 15 SARDS‐affected and 
16 unaffected (control) Dachshunds, arranged by chromosome (x axis). Line denotes genome‐wide significance based on Bonferroni‐corrected P‐
values. Genomic inflation factor = 1
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diagnosed with SARDS and 16 Dachshunds considered unaf-
fected (controls). Of these samples, 15 affected and 16 con-
trol samples passed filters and quality control. A genomic 
inflation factor (λ) of 1 was observed, and 404 619 SNPs re-
mained after quality control.
No SNPs were of genome‐wide statistical significance 
(PBonferroni < 0.05 (Figure 1). Six of the nine most statisti-
cally significant SNPs were found on canine chromosome 
(CFA) 12, and five of these six were within the coding re-
gion of the major histocompatibility complex (MHC) (Table 
1). Statistically significant genome‐wide associations to the 
MHC are uncommon in dogs; therefore, this association was 
investigated further by MHC genotyping a larger cohort of 
SARDS‐affected and control Dachshunds.
3.2 | MHC genotyping for DLA‐DRB1, 
DQA1, and DQB1
In all, DNA samples from 34 Dachshunds affected with 
SARDS and 66 control Dachshunds were typed for three 
DLA class II genes. Of the 66 control Dachshunds, 31 sam-
ples were taken from the CGB database. The entire study 
population contained 19 different DLA‐DRB1 alleles, 8 dif-
ferent DLA‐DQA1 alleles, and 12 different DLA‐DQB1 al-
leles (Table 2, Figure 2), which combined into 25 different 
haplotypes (Table 3, Figure 3). A previously unidentified 
allele (hereafter “DLA‐DRB1*DH‐Davis”) was detected in 
2 heterozygous dogs as part of the same novel haplotype 
(hereafter referred to as “DLA‐DRB1*DH‐Davis/DQA*003
01/DQB*00401”).
The allele frequency of DLA‐DRB1*09401 was sig-
nificantly higher in affected dogs (20.6%) than in control 
dogs (6.1%; OR = 4.0; CI = 1.6‐10.1; P = 0.0032; Table 2; 
Figure 2). This allele was found in a single haplotype (DLA‐
DRB1*09401/DQA*00101/DQB‐DQBC1) which therefore 
shared the identical frequencies as the allele alone. Three al-
leles were found significantly less frequently in affected dogs 
than in control dogs; DLA‐DQB1*00101, DLA‐DQA1*00901, 
and a DLA‐DRB1 allele that aligned with a sequence referred 
to as “DRB‐T” in GenBank (Table 2; Figure 2). One of the 
haplotypes that contained the DRB‐T allele (DLA‐DRB‐T/
DQA*00101/DQB‐DQBC1) was also found significantly 
less commonly in affected animals (10.3%) than in control 
animals (22.0%; OR = 0.41; CI = 0.17‐0.99; P = 0.0466; 
Table 3; Figure 3). Finally, significantly more affected dogs 
(29.4%) than control dogs (12.1%) were homozygous at all 
three locations (OR = 3.0; CI = 1.1‐8.6; P = 0.038).
4 |  DISCUSSION
In this study, we identified four alleles and two haplotypes 
across three DLA class II genes (DLA‐ DRB1, DLA‐DQA1, 
and DLA‐DQB1) that demonstrated statistically significant 
association with SARDS in Dachshunds. The region of in-
terest on CFA12 was initially identified through a GWAS, 
although the association was not statistically significant. 
However, as the MHC is one of the most highly polymor-
phic regions of the genome, a GWAS is very unlikely to 
identify significance of an association in this region.12 
Therefore, three DLA class II genes were sequenced in a 
larger population of Dachshunds so as to better identify a 
true association.
In the present study, the allele DLA‐DRB1*09401 and 
its parent haplotype DLA‐DRB1*09401/DQA*00101/DQB‐
DQBC1 were overrepresented in affected dogs, suggest-
ing a higher risk of SARDS in dogs possessing this allele. 
However, this haplotype also appeared in control dogs, and 
only about one third of affected dogs possessed at least one 
copy of the allele. Therefore, this is inconsistent with a sin-
gle causative mutation for the disease. Rather, it is possible 
that this allele confers higher risk of developing SARDS, or 
is associated with this syndrome for some other reason. By 
contrast, the alleles DLA‐DQB1*00101, DLA‐DQA1*00901, 
SNP Chromosome Position (bp) χ2 P‐value
AX‐167952531 12 8 184 905 16.95 3.831E‐5
AX‐167543896 12 3 268 272 15.33 9.018E‐5
AX‐167539614 19 48 026 694 15.33 9.018E‐5
AX‐167921313 1 106 754 682 14.48 1.414E‐4
AX‐167811284 3 63 770 730 14.11 1.723E‐4
AX‐167798146 12 1 936 523 14.11 1.723E‐4
AX‐167837680 12 1 939 111 14.11 1.723E‐4
AX‐167809780 12 1 950 348 14.11 1.723E‐4
AX‐167698387 12 1 956 879 14.11 1.723E‐4
Base pair (bp) positions of SNPs are based on CanFam3.1 assembly. The approximate location of the major 
histocompatibility complex (MHC) coding region in CanFam 3.1 is CFA12: 800 000‐2 600 000 Mb.
T A B L E  1  Nine single nucleotide 
polymorphisms (SNPs) identified as most 
closely associated with sudden acquired 
retinal degeneration syndrome (SARDS) 
during a genome‐wide association study 
(GWAS) in 15 SARDS‐affected and 16 
control Dachshunds
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T A B L E  2  Prevalence of different alleles of three dog leukocyte antigen (DLA) class II genes (DLA‐DRB1, DLA‐DQA1, and DLA‐DQB1) in 
34 Dachshunds with sudden acquired retinal degeneration (SARDS) and 66 unaffected (control) Dachshunds
DLA Gene/allele
SARDS‐affected dogs Control dogs
P‐value OR (95% CI)Number Frequency Number Frequency
DQA1
*00101 43 0.63 69 0.52 0.1402 1.57 (0.86‐2.86)
*00901 8 0.12 38 0.29 0.0087 0.33 (0.14‐0.76)
*00601 13 0.19 16 0.12 0.1865 1.71 (0.77‐3.81)
*00201 1 0.01 5 0.04 0.3804 0.38 (0.04‐3.31)
*00301 1 0.01 3 0.02 0.7033 0.64 (0.06‐6.29)
*00401 0 0 1 0.01 0.7854 0.64 (0.03‐15.92)
*005011 1 0.01 0 0 0.2796 5.89 (0.24‐146.51)
*00801 1 0.01 0 0 0.2796 5.89 (0.24‐146.51)
DQB1
C1 (AH006318.2) 22 0.32 37 0.28 0.5257 1.23 (0.65‐2.32)
*00101 8 0.12 40 0.30 0.0050 0.31 (0.13‐0.70)
*00201 21 0.31 25 0.19 0.0594 1.91 (0.97‐3.75)
*02301 9 0.13 15 0.11 0.6999 1.19 (0.49‐2.88)
*01303 1 0.01 5 0.04 0.3804 0.38 (0.04‐3.31)
*00802 0 0 5 0.04 0.2314 0.17 (0.01‐3.11)
*00401 1 0.01 3 0.02 0.7033 0.64 (0.07‐6.29)
*02002 1 0.01 1 0.01 0.6373 1.96 (0.12‐31.75)
*00301 3 0.04 0 0 0.0811 14.16 (0.72‐278.23)
*00701 1 0.01 0 0 0.2796 5.89 (0.24‐146.51)
*00502 1 0.01 0 0 0.2796 5.89 (0.24‐146.51)
*01701 0 0 1 0.01 0.7854 0.64 (0.03‐15.92)
DRB1
‐U (DQ056278.1) 20 0.29 25 0.19 0.0952 1.78 (0.90‐3.52)
‐T (DQ056277.1) 7 0.10 31 0.23 0.0284 0.37 (0.16‐0.90)
‐Z (DQ056280.1) 5 0.07 23 0.17 0.0592 0.38 (0.14‐1.04)
*09401 14 0.21 8 0.06 0.0032 4.02 (1.59‐10.14)
*01502 6 0.09 10 0.08 0.7582 1.18 (0.41‐3.40)
*00203 2 0.03 13 0.10 0.0980 0.28 (0.06‐1.27)
‐W (DQ056281.1) 6 0.09 8 0.06 0.4706 1.50 (0.50‐4.51)
*04801 1 0.01 5 0.04 0.3804 0.38 (0.04‐3.31)
*01701 0 0 4 0.03 0.2952 0.21 (0.01‐3.93)
*07301 1 0.01 1 0.01 0.6373 1.96 (0.12‐31.75)
*DH‐Davis 1 0.01 1 0.01 0.6373 1.96 (0.12‐31.75)
*01503 1 0.01 0 0 0.2796 5.89 (0.24‐146.51)
*02901 0 0 1 0.01 0.7854 0.64 (0.03‐15.92)
*0802 0 0 1 0.01 0.7854 0.64 (0.03‐15.92)
*102:01 1 0.01 0 0 0.2796 5.89 (0.24‐146.51)
*01301 1 0.01 0 0 0.2796 5.89 (0.24‐146.51)
*01504 1 0.01 0 0 0.2796 5.89 (0.24‐146.51)
(Continues)
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and DLA‐DRB‐T, as well as the haplotype DLA‐DRB‐T/
DQA*00101/DQB‐DQBC1, were under‐represented in af-
fected dogs, suggesting a protective effect. Again, these 
potentially protective alleles were found in some SARDS‐af-
fected dogs, and not all control dogs possessed one of the 
protective alleles. Even when evaluated in combination with 
the risk allele, there were SARDS‐affected dogs that pos-
sessed the protective allele and not the risk allele, as well as 
control dogs that possessed the risk allele and not the protec-
tive allele. These findings reinforce that DLA type does not 
appear to be solely responsible for susceptibility to develop-
ing SARDS.
Associations between MHC genes and autoimmune 
diseases have been reported in humans13-15 as well as ani-
mals.16-18 In one study in Doberman pinschers, two of the 
same DLA alleles suggested by our study to be protective 
for development of SARDS (DLA‐DQA1*00901 and DLA‐
DQB1*00101) were also potentially protective against 
Doberman hepatitis.19 Like SARDS, Doberman hepatitis is 
a poorly understood disease seen more commonly in female 
DLA Gene/allele
SARDS‐affected dogs Control dogs
P‐value OR (95% CI)Number Frequency Number Frequency
*01201 0 0 1 0.01 0.7854 0.64 (0.03‐15.92)
*EH‐13 
(EU528639.1)
1 0.01 0 0 0.2796 5.89 (0.24‐146.51)
Where GenBank sequence of alignment is not named according to standard practice, accession number is provided in parentheses. A previously unidentified DLA‐DRB1 
allele is referred to as DRB1*DH‐Davis. Alleles in bold type are those whose frequency was significantly higher or lower in SARDS‐affected animals.
CI, confidence interval; OR, odds ratio.
T A B L E  2  (Continued)
F I G U R E  2  Dog leukocyte antigen 
(DLA) typing results for 34 Dachshunds 
affected with sudden acquired retinal 
degeneration syndrome (SARDS) and 66 
unaffected (control) Dachshunds. A, DLA‐
DRB1 allele frequencies in affected dogs. 
B, DLA‐DRB1 allele frequencies in control 
dogs. C, DLA‐DQA1 allele frequencies 
in affected dogs. D, DLA‐DQA1 allele 
frequencies in control dogs. E, DLA‐DQB1 
allele frequencies in affected dogs. F, DLA‐
DQB1 allele frequencies in control dogs. 
Statistically significant differences between 
affected and control dogs are indicated with 
an asterisk, and P‐values are written in the 
key
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dogs and hypothesized to have an autoimmune etiology. 
Despite the identification of some novel genetic associations 
in the present study, the mechanism by which variations in the 
MHC might predispose an animal or human to autoimmune 
disease remains unknown. It has been hypothesized that the 
role of the MHC in antigen presentation to T lymphocytes 
during development of immunologic tolerance may be in-
volved,20-22 but a precise mechanism has not been identified.
T A B L E  3  Prevalence of dog leukocyte antigen (DLA) class II haplotypes in 34 Dachshunds with sudden acquired retinal degeneration 
(SARDS) and 66 unaffected (control) Dachshunds
DLA haplotype 
(DLA‐DRB1/DQA1/
DQB1)
SARDS‐affected dogs Control dogs
P‐value OR (95% CI)Number Frequency Number Frequency
U/*00101/*00201 20 0.29 25 0.19 0.0952 1.78 (0.90‐3.52)
T/*00101/C1 7 0.10 29 0.22 0.0466 0.41 (0.17‐0.99)
Z/*00901/*00101 5 0.07 23 0.17 0.0592 0.38 (0.14‐1.04)
*09401/*00101/C1 14 0.21 8 0.06 0.0032 4.02 (1.59‐10.14)
*01502/*00601/*02301 6 0.09 10 0.08 0.7582 1.18 (0.41‐3.40)
*00203/*00901/*00101 2 0.03 13 0.10 0.0980 0.28 (0.06‐1.27)
W/*00601/*02301 1 0.01 5 0.04 0.3804 0.38 (0.04‐3.31)
*04801/*00101/*00802 0 0 5 0.04 0.2314 0.17 (0.01‐3.11)
*01701/*00201/*01303 0 0 4 0.03 0.2952 0.21 (0.01‐3.93)
W/*00901/*00101 1 0.01 2 0.01 0.9804 0.97 (0.09‐10.89)
W/*00601/*02002 1 0.01 1 0.01 0.6373 1.96 (0.12‐31.75)
W/*00601/*00301 3 0.04 0 0 0.0811 14.16 (0.72‐278.23)
T/*00101/*00101 0 0 2 0.01 0.5353 0.38 (0.02‐8.05)
*DH‐
Davis/*00301/*00401
1 0.01 1 0.01 0.6373 1.96 (0.12‐31.75)
*07301/*00201/*01303 1 0.01 1 0.01 0.6373 1.96 (0.12‐31.75)
*01201/*00401/*01701 0 0 1 0.01 0.7854 0.64 (0.03‐15.92)
*02901/*00301/*00401 0 0 1 0.01 0.7854 0.64 (0.03‐15.92)
*0802/*00301/*00401 0 0 1 0.01 0.7854 0.64 (0.03‐15.92)
*102:01/*00101/*00201 1 0.01 0 0 0.2796 5.89 (0.24‐146.51)
*01504/*00601/*02301 1 0.01 0 0 0.2796 5.89 (0.24‐146.51)
Unidentified 4 0.06 0 0 N/A N/A
A new haplotype containing the novel DRB1*DH‐Davis allele was identified in two dogs. Haplotypes in bold type are those whose frequency was significantly higher or 
lower in SARDS‐affected animals.
CI, confidence interval; OR, odds ratio.
F I G U R E  3  Dog leukocyte antigen (DLA) typing results for 34 Dachshunds affected with sudden acquired retinal degeneration syndrome 
(SARDS) and 66 unaffected (control) Dachshunds. A, haplotype frequencies in affected dogs. B, haplotype frequencies in control dogs. Statistically 
significant differences between affected and control dogs are indicated with an asterisk, and P‐values are written in the key
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As the etiology of SARDS is not yet understood, iden-
tification of a genetic association between this disease and 
some DLAs that bears close resemblance to associations 
found between the MHC and a number of autoimmune dis-
eases is important and supports further investigation of an 
autoimmune etiology for SARDS. However, spurious asso-
ciations are often found when genotyping the DLA in this 
manner, especially in dog breeds with relatively few haplo-
types.23 However, our study identified twenty‐five different 
haplotypes in the population studied, making Dachshunds a 
more genetically diverse breed than some of those previously 
studied,24,25 and lowering the likelihood that this exerted an 
unwanted effect. Likewise, while the MHC may play a role 
in SARDS, other genetic and/or environmental factors are 
likely involved. In order to identify other genetic factors, a 
larger number of SARDS‐affected and control dogs should 
be assessed in a GWAS. The GWAS performed here was not 
subject to significant population stratification, and a large 
number of SNPs were used; however, it had a modest number 
of samples more appropriate for the identification of a simple 
recessive locus.26
In conclusion, we have identified several alleles and hap-
lotypes of DLA class II genes which appear to confer ei-
ther susceptibility to or protection against development of 
SARDS in the Dachshund. If these are true associations, their 
presence supports the hypothesis that SARDS has an autoim-
mune etiology, and this warrants future research.
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